Evaluating the management of anaphylaxis in US emergency departments: Guidelines vs. practice

W. Scott Russell, Judith Rosen Farrar, Richard Nowak, Daniel P. Hays, Natalie Schmitz, Joseph Wood, Judi Miller

1 Pediatric Emergency Department, Medical University of South Carolina, Charleston, SC 29425, USA
2 Life Sciences Press, Canandaigua, NY, USA
3 Department of Emergency Medicine, Henry Ford Health System, Detroit, MI, USA
4 University of Arizona Medical Center, Tucson, AZ, USA
5 DeKalb Medical Center, Atlanta, GA, USA
6 Mayo Clinic Arizona, Scottsdale, AZ, USA
7 SRxA, Washington, DC, USA

Corresponding Author: W. Scott Russell, Email: ruscott@musc.edu

BACKGROUND: Anaphylaxis is characterized by acute episodes of potentially life-threatening symptoms that are often treated in the emergency setting. Current guidelines recommend: 1) quick diagnosis using standard criteria; 2) first-line treatment with epinephrine; and 3) discharge with a prescription for an epinephrine auto-injector, written instructions regarding long-term management, and a referral (preferably, allergy) for follow-up. However, studies suggest low concordance with guideline recommendations by emergency medicine (EM) providers. The study aimed to evaluate how emergency departments (EDs) in the United States (US) manage anaphylaxis in relation to guideline recommendations.

METHODS: This was an online anonymous survey of a random sample of EM health providers in US EDs.

RESULTS: Data analysis included 207 EM providers. For respondent EDs, approximately 9% reported using agreed-upon clinical criteria to diagnose anaphylaxis; 42% reported administering epinephrine in the ED for most anaphylaxis episodes; and <50% provided patients with a prescription for an epinephrine auto-injector and/or an allergist referral on discharge. Most provided some written materials, and follow-up with a primary care clinician was recommended.

CONCLUSIONS: This is the first cross-sectional survey to provide "real-world" data showing that practice in US EDs is discordant with current guideline recommendations for the diagnosis, treatment, and follow-up of patients with anaphylaxis. The primary gaps are low (or no) utilization of standard criteria for defining anaphylaxis and inconsistent use of epinephrine. Prospective research is recommended.

KEY WORDS: Anaphylaxis; Guidelines; Epinephrine (adrenaline); Allergic reaction; Life-threatening reaction; Emergency department; Epinephrine autoinjector; Self-injectable epinephrine

INTRODUCTION

Anaphylaxis is a condition that crosses medical boundaries. Though usually allergic in nature, the acute anaphylaxis episode is most frequently treated by an emergency medicine (EM) health professional and not an allergy specialist. For the US, a review of anaphylaxis in children and adolescents over a 6-year period reported that 71% of cases were treated at an emergency department (ED)
or urgent care center.[11] The number of annual ED visits for anaphylaxis in the US is estimated to be as high as 500,000.[2]

Despite the primary role of EM in the initial management of anaphylaxis, the majority of reports about anaphylaxis including management guidelines and practice parameters are published in allergy journals.[3–7] In the past decade, these documents have been published by multiple subspecialty groups (e.g., allergy, emergency medicine, pediatrics) in an effort to work together to develop clinical criteria for diagnosing anaphylaxis and specific recommendations for its management. Nonetheless, on a global level, evidence continues to point to both practice and knowledge gaps for emergency health professionals, including low concordance with guideline-recommended treatment, even in patients who were clearly diagnosed with anaphylaxis by medical record or by ICD-9 code.[2,8–17]

To date, only one study has evaluated the implementation of anaphylaxis guideline recommendations.[16] That study, performed using the transnational anaphylaxis registry of Germany, Austria, and Switzerland, confirmed major discrepancies in treatment and follow-up and recommended a revised approach to management, including training and education. No data exist for the US.

In an effort to better understand how US EDs use anaphylaxis guidelines, we conducted an online survey of US ED health professionals focusing on the three components of management common to all guidance documents:

1. Diagnosis. Are the current clinical criteria for identifying anaphylaxis as published in the National Institutes of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN) 2nd Symposium,[5] the 2010 US Practice Parameters,[4] or the World Allergy Organization (WAO) Guidelines,[3,6] being applied in clinical practice?

2. Treatment. Is epinephrine being used as the first-line agent for treating all episodes of anaphylaxis—even those with mild or single system symptoms and those in which the diagnosis is only suspected?[3–7,18]

3. Discharge. Do ED discharge plans meet current guideline recommendations (i.e., a prescription for epinephrine, written instructions for self-management, and a physician—preferably, allergist-referral for follow-up)?[3–7]

METHODS

An on-line survey was conducted between March 19 and April 30, 2012 as a potential pilot project for a more robust evaluation to be developed. The online Survey Monkey tool (SurveyMonkey.com, LLC; Palo Alto, CA) was selected for its simplicity, scalability, and relatively quick data capture and analysis.

The survey included dichotomous and nominal-polytomous closed-ended questions, with additional open-ended responses invited for some queries. The survey questions were developed initially during a discussion at a multidisciplinary roundtable meeting, Anaphylaxis in Emergency Medicine (July 2011; Chicago, IL) that included physicians, nurse practitioners, physician assistants, and pharmacists involved in EM.[17] Following some revision, the questions were approved by the authors, who were among the roundtable attendees.

Non-targeted distribution methods were utilized and were conducted independently of the authors and sponsors. EM providers were invited to participate in the survey by notification posted on the website of the Journal of Emergency Medicine (Elsevier, Inc.). Additionally, a randomly sampled national group of 3000 hospital-based EM physicians, nurse practitioners, and physician assistants received an email invitation to participate from a third party provider (List Information Service Technology, Inc., Midland Park, NJ). The first 150 respondents received a stipend of $50. Subsequent respondents were not incentivized or remunerated.

Data analysis

Responses to multiple-choice questions were managed by SurveyMonkey and were directly exported to an Excel spreadsheet (Microsoft Corp., Redmond, WA). The data were deemed evaluable if the respondent was from a US ED and completed at least 80% of the questions.

Data from the multiple-choice questions were evaluated by response count and response percentage. Not all respondents answered all questions; therefore, the results were calculated according to responses to a particular question.

Open-ended responses were reviewed individually by two of the authors. The survey can be accessed at https://www.surveymonkey.com/s/anaphylaxispracticegaps.

RESULTS

A total of 207 EM health professionals responded to the survey, and 166 (80.2%), representing 26 states, completed all questions: 140 physicians, 18 physician assistants, 7 nurses (including five nurse practitioners), and one who did not identify his/her practice.

Diagnosis

Almost 90% of respondents reported that their EDs did not use a written definition of anaphylaxis (Figure 1). Thirty-two of 196 (16.3%) respondents stated that their EDs used a definition based on an established set of criteria

www.wjem.org
(question 2): 17 of these respondents (8.9% of the total) reported using definitions based on consensus criteria recommended by the NIAID/FAAN 2nd Symposium\(^5\) (1.6%), the 2010 US Practice Parameters\(^4\) (4.2%), or the WAO guidelines\(^3,6\) (3.1%) as the source of their definition.

**Treatment**

When asked whether their ED used a standard protocol for treating patients with anaphylaxis (question 3), 63 of 196 respondents (31.8%) said yes, and 118 (59.6%) said no. The remainder did not know.

Eighty-four of 196 respondents (42.4%) reported that in their EDs the majority of patients (defined as >75%) seen for anaphylaxis received epinephrine as part of their acute care management (Figure 2); 79 (40.3%) reported that ≤50% of patients seen in their EDs received treatment with epinephrine.

**Discharge**

Ninety-five (48.2%) of the 196 respondents reported that >75% of patients seen for anaphylaxis were discharged with a prescription for an epinephrine auto-injector (Figure 3). However, 61 respondents (31%) reported that in their ED ≤50% of patients received such a prescription.

Two distinct subgroups were identified by the respondents as more likely to receive a prescription for epinephrine at discharge (Figure 4): those with reactions to insect stings or foods (76% and 61% received a prescription, respectively).

The top three barriers to prescribing epinephrine described by 176 respondents were lack of staff/provider awareness/education (61 respondents, 34.7%); concern about side effects, particularly in older patients (57 respondents, 32.4%); and cost (45 respondents, 25.6%). Other concerns cited included a lack of standard protocols and time. In regards to time, several respondents specifically commented that they did not have the time or, in some cases, the training materials to provide appropriate patient education and follow-up.

At discharge, most patients were advised to follow-up with a physician (Figure 5). Of 198 respondents, 171 (86.4%) recommended that the patient see the primary

---

**Figure 1.** Use of a written definition of anaphylaxis in US EDs. Respondents answered the question: Does your department have a written definition of anaphylaxis? (n=204).

**Figure 2.** Percentage of patients seen in the ED for anaphylaxis who were treated with epinephrine while in the ED. Respondents answered the question: What percentage of patients treated for anaphylaxis in your ED receive epinephrine as part of their acute care management? (n=196).

**Figure 3.** Percentage of patients seen in the ED for anaphylaxis who were discharged with a prescription for self-injectable epinephrine. Respondents answered the question: What percentage of patients treated for anaphylaxis in your ED is discharged with a prescription for self-injectable epinephrine? (n=197).

**Figure 4.** The likelihood of anaphylaxis patient subgroups being discharged with a prescription for self-injectable epinephrine. Respondents answered the question: Are there particular patient populations you are more likely to prescribe self-injectable epinephrine to at discharge? (n=188).
Either criteria 1 Or criteria 2 Or criteria 3

DISCUSSION

This is the first cross-sectional survey of EM professionals to evaluate management of anaphylaxis in US EDs. The data confirm a wide variability in practice and substantial gaps in the application of guideline-based recommendations for the diagnosis, treatment, and follow-up care of these patients. The survey, while relatively simple in design and limited in scope, captured critical points regarding all three components of management.

The primary gap identified is low utilization of a standard definition of anaphylaxis: 90% of EDs in this survey did not use a formal definition of anaphylaxis despite the agreed-upon criteria in both allergy and EM literature (Table 1). Lack of a definition affects all components of care and likely accounts for the substantial diagnostic disparity observed in the “real world.” It has been estimated that at least 50% of anaphylaxis episodes are misdiagnosed in the ED when the diagnostic criteria of current guidelines are not used. More importantly for the patient, low recognition of anaphylaxis in the ED may delay the treatment with epinephrine and result in comorbidity, hospitalization and death.

However, even when the patient has been appropriately diagnosed with anaphylaxis, epinephrine may not be given as the first-line treatment. This is in direct contrast to the recommendations of all current practice guidelines for anaphylaxis. It may reflect the lack of standard protocols for anaphylaxis treatment as reported by approximately two-thirds of the EM providers who participated in this survey. Alternatively, it may represent a low awareness of guideline recommendations and mistaken concerns about the safety of IM epinephrine for anaphylaxis (i.e., confusion about adverse physiological effects associated with epinephrine administered at the intravenous doses used for cardiopulmonary resuscitation).

With regard to discharge recommendations for patients seen in the ED for an episode of anaphylaxis or serious allergic reaction, only one (provision of written information) was regularly followed. The others (prescription of an epinephrine auto-injector and referral to an allergist) occurred less consistently. Nevertheless, almost all responding EDs recommended that patients follow up with their PCP. It is unclear whether this recommendation was specific to anaphylaxis management or whether it reflected a general discharge requirement that all patients be told to contact their PCP after an ED visit, independent of specific diagnosis. Furthermore, the critical information would be the percentage of patients who...

Table 1. Clinical criteria for the diagnosis of acute anaphylactic episode[3–7] Anaphylaxis is highly likely when any one of the following 3 criteria is fulfilled

<table>
<thead>
<tr>
<th>Either criteria 1</th>
<th>Or criteria 2</th>
<th>Or criteria 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute onset (min–several hr) of an illness involving the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula) and at least 1 of the following:</td>
<td>Two or more of the following occurring rapidly (min–several hr) after exposure to a likely allergen for the patient:</td>
<td>Reduced BP occurring rapidly (min–several hr) after exposure to a known allergen for the patient:</td>
</tr>
<tr>
<td>a. Respiratory compromise (e.g., dyspnea, wheezing-bronchospasms, stridor, reduced PEF, hypoxemia)</td>
<td>a. Involvement of the skin-mucosal tissue (e.g., generalized hives, itch–flush, swollen lips-tongue-uvula)</td>
<td>a. Infants and children: low systolic BP (age-specific) or &gt;30% decrease in systolic BP</td>
</tr>
<tr>
<td>b. Reduced BP or associated Sx of end-organ dysfunction (e.g., hypotonia, syncope)</td>
<td>b. Respiratory compromise (e.g., dyspnea, wheezing-bronchospasms, stridor, reduced PEF, hypoxemia)</td>
<td>b. Adults: systolic BP &gt;90 mmHg or &gt;30% decrease from baseline</td>
</tr>
<tr>
<td>c. Reduced BP or associated Sx of end-organ dysfunction (e.g., hypotonia, syncope)</td>
<td>c. Reduced BP or associated Sx of end-organ dysfunction (e.g., hypotonia, syncope)</td>
<td>d. Before persistent: persistent GI Sx (e.g., cramps, abdominal pain, vomiting)</td>
</tr>
<tr>
<td>d. Before persistent: persistent GI Sx (e.g., cramps, abdominal pain, vomiting)</td>
<td>d. Before persistent: persistent GI Sx (e.g., cramps, abdominal pain, vomiting)</td>
<td></td>
</tr>
</tbody>
</table>

BP: blood pressure; GI: gastrointestinal; hr: hours; min: minutes; PEF: peak expiratory flow; Sx: symptoms
follow-through on the referral, and we did not collect these data. However, using a similar model in which follow-up outpatient appointments are strongly recommended (children seen for a severe asthma exacerbation in a pediatric ED) a retrospective cohort study reported that only 12% of patients followed up with their PCP. This could be an area of further study.

Our data are similar to practice gaps identified in the study assessing implementation of anaphylaxis guidelines in Germany, Austria, and Switzerland as well as in an earlier global review of anaphylaxis emergency care.

To date, there is no systematic review focusing on anaphylaxis management in US EDs, nor are there any studies specifically evaluating gaps in practice in relation to guideline-based recommendations for managing anaphylaxis. However, we were able to find 13 US studies (8 in adults, 5 in adolescents and children) in which individual gaps in diagnosis, treatment, and follow-up could be inferred. The applicable data are summarized in Table 2.

Table 2. Gaps where clinical practice differs from guideline recommendations for managing the anaphylaxis in the ED, indirectly suggested by studies of the incidence or management of anaphylaxis at US EDs. All studies evaluated US data only and used a definition of anaphylaxis based on current guideline criteria. Gaps in diagnosis, ED treatment, and discharge are noted.

<table>
<thead>
<tr>
<th>Citation</th>
<th>Study Design</th>
<th>Description</th>
<th>Population</th>
<th>Gaps</th>
<th>Definition/Dx</th>
<th>Treatment in ED</th>
<th>At discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campbell et al., 2010 [20]</td>
<td>Retrospective, consecutive cohort study</td>
<td>Compared dx and tx of ED patients ≥ 50 years and &lt; 50 years who met NAIAD-FAAN criteria for anaphylaxis between 4/2008 and 6/2010</td>
<td>n=220 patients</td>
<td>Anaphylaxis was often not dx in ED patients presenting with allergic reactions despite multisystem organ involvement (authors suggested this related to 1) lack of universally accepted dx criteria; 2) low recognition of ‘vague’ sx as part of dx, (eg, shortness of breath, light-headedness); 3) lack of sensitive/ specific biomarkers</td>
<td>Prescription for epinephrine, 63.8%, overall; 40.7% for patients ≥ 50 yr, and 32.1% for patients ≥ 65 yr</td>
<td>Post-ED allergist evaluation, 36.4%</td>
<td></td>
</tr>
<tr>
<td>Campbell et al., 2008 [19] (also reported in Decker et al., 2008)</td>
<td>Retrospective medical record review</td>
<td>Assessed incidence of anaphylaxis (1990–2000) based on dx criteria in random sample of 2,442 patients at tertiary care AMC and community hospital EDs in Olmsted Co, Minn’</td>
<td>n=848 patients: 248 with ICD-9 (or HCFA) codes related to anaphylaxis; 600 with associated dx</td>
<td>Patients meeting criteria for anaphylaxis: 157 of 248 with ICD-9 codes; 54 600 with associated dx (authors suggested variability due to the lack of universally accepted definition of anaphylaxis)</td>
<td>Prescription for epinephrine, 36.6% (more likely in patients who received epinephrine in ED)</td>
<td>Referral to allergist, 31.3% (more likely for prescribed epinephrine at discharge)</td>
<td></td>
</tr>
<tr>
<td>Clark et al., 2004 [20]</td>
<td>Retrospective cohort study</td>
<td>Evaluated ED visits for physician-dx’d, food-related acute allergic reactions over a 1-yr period in 21 North American AMCs (the Multicenter Airway Research Collaboration)</td>
<td>n=678 patients randomly selected from 5296 identified charts using food allergy codes and less specific related ICD-9 codes</td>
<td>Epinephrine, 16% Diphenhydramine, 90% Parenteral CCS, 50%</td>
<td>Referral to allergist, 12% Written instructions for avoidance, 40% Wide variability in discharge plans noted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clark et al., 2005 [21]</td>
<td>Retrospective cohort study</td>
<td>Evaluated ED visits for physician-dx’d insect sting allergic reactions over a 1-yr period in 15 North American AMCs (the Multicenter Airway Research Collaboration)</td>
<td>n=617 patients randomly selected from 1523 identified charts using specific allergy codes and less specific related ICD-9 codes</td>
<td>For patients with anaphylaxis: Epinephrine, 16% Anhistimines, 70% Parenteral CCS, 49%</td>
<td>Patients with systemic reactions (i.e., anaphylaxis or at risk of anaphylaxis): Prescription for epinephrine, 27% Referral to allergist, 20% Written instructions for avoidance, 15%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gaeta et al., 2007 [22]</td>
<td>Retrospective review of nationally representative sample of ED visits using the National Hospital Ambulatory Medical Care Survey</td>
<td>Assessed national trends in ED visits for management of anaphylaxis (1993–2004) using ICD-9 codes for acute allergic reactions and anaphylaxis</td>
<td>n=12.4 million ED visits</td>
<td>Epinephrine, 11% Most ED physicians relied on 2nd line agents, particularly H1 antagonists, to tx acute allergic reactions Substantial controversy about how/when to use epinephrine for acute allergic reactions in ED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harduar-Morano et al., 2010 [23]</td>
<td>Retrospective review of ED data from the Florida Agency for Health Care Administration</td>
<td>Assessed FL anaphylaxis cases (2005–2006) by ICD-9-CM codes or using an algorithm based on the 2nd Symposium criteria</td>
<td>n=3 024 records of anaphylaxis episodes (ICD-9 codes, 1 283: algorithm, 1 741)</td>
<td>Lack of standard definition and dx criteria resulted in cases not dx’d or mis-dx’d: 58% of cases were missed using ICD-9 codes alone</td>
<td>Epinephrine: ICD-9 cases (n=111), 10%; algorithm cases (n=180), 11%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

To be continued from next page
<table>
<thead>
<tr>
<th>Study</th>
<th>Design/Method</th>
<th>Cases meeting criteria for anaphylaxis (%)</th>
<th>Criteria of</th>
<th>Current Survey of US ED Providers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross et al., 2008</td>
<td>2-mo retrospective review of the National Electronic Injury Surveillance System database</td>
<td>n=173 ED-food allergic events reported at 34 sites</td>
<td>38% received dx; 62% did not</td>
<td>Epinephrine, 19% Antihistamines, 87% Parenteral CCS, 65%</td>
</tr>
<tr>
<td>Rudders et al., 2010</td>
<td>Retrospective medical record review</td>
<td>n=153 patients</td>
<td>In patients with systemic reactions (i.e., anaphylaxis or at risk of anaphylaxis):</td>
<td>Epinephrine, 9% Antihistamines, 76% Parenteral CCS, 55%</td>
</tr>
<tr>
<td>Pediatric studies</td>
<td></td>
<td>n=229 422 patients ≤18 yr enrolled in HMO in WA between 3/1/1991 and 12/31/1997</td>
<td>753 possible cases, 67 anaphylaxis episodes identified by ICD-9 codes and 18 more by sampling related dx (authors suggested this reflected 1 lack of a std case definition: 2 variability among criteria used)</td>
<td>Epinephrine, 79% Parenteral antihistamine, 51% Parenteral CCS, 34%</td>
</tr>
<tr>
<td>Bohlke et al, 2004</td>
<td>Retrospective review of dx</td>
<td>n=38 480 children</td>
<td>Disparities in etiology of food allergy related to under dx and underestimates of childhood food allergy in the US</td>
<td>Disparities in management of food allergy noted</td>
</tr>
<tr>
<td>Gupta et al, 2011</td>
<td>Randomized, population-based, cross-sectional survey of US homes with children ≤ 18 yr</td>
<td>n=213 anaphylaxis episodes in 192 patients ≤18 yr enrolled at 3 EDs in Boston, MA (2001–2006)</td>
<td>Significant miscoding of anaphylaxis: 71% of episodes received ICD-9 code for allergic rx, not anaphylaxis (confusion related to lack of standard dx criteria)</td>
<td>Epinephrine, overall: 79%; 75% of allergic reactions, 81% of coded anaphylaxis Histamine-1-receptor antagonists, 92% Histamine-2-receptor antagonists, 46% Parenteral CCS, 89%</td>
</tr>
<tr>
<td>Huang et al, 2012</td>
<td>Retrospective case review</td>
<td>n=1 255 patients</td>
<td>Epinephrine, 20%</td>
<td>Prescription for epinephrine at ED discharge, 63%</td>
</tr>
<tr>
<td>Rudders et al., 2010</td>
<td>Retrospective medical record review</td>
<td>n=124 patients</td>
<td>Referral to allergist, 33% Written instructions for avoidance, 36%</td>
<td>Prescription for epinephrine, 63%</td>
</tr>
<tr>
<td>Russell et al, 2010</td>
<td>Cross-sectional descriptive study</td>
<td>n=207 EM providers</td>
<td>Respondents reporting that in their EDs: Majority (&gt;75%) of patients received epinephrine in ED:</td>
<td>Respondents reporting that in their EDs: Majority (&gt;75%) of patients received prescription for epinephrine: 48% ≤50% of patients received prescription for epinephrine: 31% Referral to allergist for &gt;50% of patients: 42%; for &gt;75% of patients: 17% Written information about anaphylaxis: 95%; anaphylaxis action plan: 71%</td>
</tr>
<tr>
<td>Current Survey of US ED Providers</td>
<td></td>
<td>Respondents reporting that in their EDs: Majority (&gt;75%) of patients received epinephrine in ED:</td>
<td>Majority (&gt;75%) of patients received prescription for epinephrine: 48% ≤50% of patients received prescription for epinephrine: 31% Referral to allergist for &gt;50% of patients: 42%; for &gt;75% of patients: 17% Written information about anaphylaxis: 95%; anaphylaxis action plan: 71%</td>
<td>Majority (&gt;75%) of patients received prescription for epinephrine: 48% ≤50% of patients received prescription for epinephrine: 31%</td>
</tr>
</tbody>
</table>

* Initially used their own criteria to define anaphylaxis (cc/signs of generalized mast cell and basophil mediator release), but later reanalyzed using criteria of 2nd symposium. AMC: Academic Medical Center; CCS: corticosteroid; dx: diagnosis; ED: Emergency Department; sx: symptom(s); tx: treatment; yr: year(s); w/o: without.
Eight studies (4 adults, 4 children) evaluated the diagnosis by ICD-9 coding with or without application of the clinical criteria recommended by anaphylaxis guidelines.\[1,8,19,27–32\] Regardless of the age of the patients or the causative trigger of the acute allergic reaction, the number of episodes receiving a diagnosis of anaphylaxis increased with application of the additional criteria, sometimes, dramatically. For example, a 2-month retrospective review of ED-food allergic events reported at 34 sites within the database of the US National Electronic Injury Surveillance System found that 62% of anaphylaxis cases did not receive the correct diagnosis. \[32\] Our data would suggest that some of these EDs probably did not use a formal definition of anaphylaxis. Would this help providers be more compliant with published guidelines? Probably. A study validating a diagnostic algorithm based on guideline recommended criteria (Table 1) to help capture previously unidentified anaphylaxis cases in the ED estimated that without the algorithm as many as 58% of patients treated for anaphylaxis in the ED (regardless of protocol or lack thereof) were also more likely to prescribe epinephrine at discharge and to recommend allergist follow-up. Similar outcomes were reported for physicians who used an anaphylaxis protocol in pediatric EDs in Spain as epinephrine use in the ED increased, so did prescription of self-injectable epinephrine on discharge. \[15\] The survey data also suggest that patients treated for (suspected) anaphylaxis to insect stings/venom or foods may be more likely to receive a prescription for an epinephrine auto-injector. Differences between this survey and published studies probably reflect specific wording of the questions and differences in data collection.

**LIMITATIONS**

The primary limitations of this survey are its reliance on participant self-reporting and the seemingly low response rate (7%, based on the email notification to 3000 ED health care professionals). As a pilot study assessing how guideline recommendations are incorporated in current ED practice, we sought a tool that would provide a relatively rapid response. The survey was not validated, and the data (based on response counts and percentages) represent a baseline. We sought 200 to 300 responses within a 6-week period, or a response rate of 7% to 10%, which was achieved, but was not sufficient for statistical analysis.

There also is the possibility that individual responses were inaccurate or biased according to the respondent's role in the ED and interest in anaphylaxis. In this regard, we noted that some respondents reported personal variation from the general practice of their ED, e.g., 76% of respondents reported always prescribing an epinephrine auto-injector for their patients on ED discharge, but only 48% reported this to be true for their ED overall.

Twenty-nine respondents did not identify their practice. A sub-analysis of the data with and without these respondents showed no difference in the trends observed. We included the data from these respondents in the survey analysis.

All regions of the US are represented in the responses to our survey, but we did not separate community hospitals from academic medical centers, nor did we evaluate the data for multiple respondents from any single health care system. Both could affect the generalizability of the results. However, while the data cannot be directly
compared, the trends from our "real world" survey are reassuringly similar to trends reported for retrospective case studies that looked individually at the diagnosis, treatment, or discharge of patients with anaphylaxis in US EDs.\[^{9,10,19,27,32}\] We believe that the limitations of our survey are not likely to be clinically significant and that the reported findings can be generalized to most American EDs.

**IMPLICATIONS**

This is the first survey to specifically evaluate the concordance between how US EDs manage anaphylaxis and guideline recommendations. The outcomes confirm deficits in all three components of care—application of diagnostic criteria, use of epinephrine in the ED, and discharge plans. Our survey suggests that despite a preponderance of documents providing specific criteria for managing anaphylaxis and studies supporting those management recommendations, current practice in US EDs has not changed and does not reflect the recommended standard for patient care. Specifically, despite repeated attempts to ensure that epinephrine is the first-line therapy for anaphylaxis, "real world" practice does not reflect this paradigm. Many articles have commented on the likely link between lack of a standard definition for anaphylaxis and diagnostic confusion resulting in low or delayed use of epinephrine in the ED, but this is the first study to provide data for that association. Most EDs (90%) used no standard definition of anaphylaxis; and for the few that did, there was a wide variability in source.

**RECOMMENDATIONS**

This survey provides a baseline for how to improve the management of anaphylaxis in the emergency setting. We believe that the first and most critical recommendation would be adoption of a standard definition of anaphylaxis that is appropriate for EM health professionals.\[^{17}\] Furthermore, the definition needs to include the two components of anaphylaxis: the acute and potentially life-threatening episode that is seen in the ED and the chronic risk for such episodes requiring follow-up and long-term management. The second recommendation is to develop programming again specific to EM that addresses the first-line role of epinephrine in the treatment of anaphylaxis. This is a two-fold recommendation: first encompassing the importance of quickly administering epinephrine in the ED even when anaphylaxis is only suspected, and second, a reminder that all patients seen in the ED for anaphylaxis are at risk for future episodes and should be discharged with a prescription for an epinephrine auto-injector. As EM professionals we are the first line of defense for many of these patients. Their ED visit provides the chance to show them, by treating them, how to administer epinephrine, what it feels like, and how quickly it works and then to inform them of the likelihood of future episodes and the actions they can take to minimize that risk.

Finally, further study is needed to determine how to bridge the specific gaps identified in this survey. We know now that in the "real EM world" adherence to the recommendations of anaphylaxis guidelines is not good,\[^{15–17}\] but we do not really understand the impact on patient outcomes as the data predominantly reflect inferences made from retrospective reviews or case series. The low concordance in clinical application itself may provide feedback on the practicality of the criteria, their acceptance, and potential barriers to implementation-independent of the patient's condition. More discussion will be needed on this point.

While clinical trials of recommended strategies cannot be conducted for ethical reasons, prospective data are needed to better evaluate the short- and long-term outcomes of implementing different management recommendations for patients with anaphylaxis seen in the ED, and perhaps could be obtained through national or international registries.

**Funding:** This manuscript was supported in part by an unrestricted educational grant from Mylan Specialty Pharmaceuticals (Basking Ridge, NJ).

**Ethical approval:** Not needed.

**Conflicts of interest:** The authors have no competing interests relevant to the present study.

**Contributors:** All authors participated in creating the online survey as well as reviewing the responses, evaluating the other studies for comparative review as described in the discussion section, and developing and editing multiple drafts of the manuscript. All authors met the ICMJE definition of authorship.

**REFERENCES**


Received January 16, 2013
Accepted after revision May 2, 2013